Sitemap Contact Worldwide Synthon company websites About Us Biopharmaceuticals Generics Products News Careers BIOPHARMACEUTICALS Synthon's success in the field of complex generic medicines has been a stimulus for us to start development of our own biopharmaceuticals in 2007. Home INTRODUCTION Synthon has been working on biotechnology since 2007 and is rapidly evolving into a specialty pharmaceutical company. SCIENTIFIC PLATFORMS Synthon started the development of biopharmaceutical medicines based on therapeutic proteins in 2007. ADC Monoclonal antibodies BIOPHARMACEUTICALS PIPELINE Since the start of Synthon’s biopharmaceutical activities in 2007, we have made significant progress with regard to development of products based on therapeutic proteins. BUSINESS DEVELOPMENT As part of the global Synthon organization, Synthon Biopharmaceuticals is well-positioned to build on the success, infrastructure and organization of the - financially independent, privately held and profitable - parent company. EVENT CALENDAR Synthon Biopharmaceuticals will be present at the following events: Science Pipeline Biopharmaceuticals Pipeline Generics Scientific platforms Partners BD Biopharmaceuticals BD Generics Products Scientific platforms Strategy Media Press releases Contact information Job Seekers Job openings Open applications Follow us facebook twitter linkedin RSS Feed Terms of use

Sitemap Contact Worldwide Synthon company websites About Us Biopharmaceuticals Generics Products News Careers Generics Introduction World class operations Generic pipeline Business development Event calendar Home Generics GENERIC PIPELINE Back Synthon's generic pipeline is focused around complex molecules in its core therapeutic areas. Tweet Science Pipeline Biopharmaceuticals Pipeline Generics Scientific platforms Partners BD Biopharmaceuticals BD Generics Products Scientific platforms Strategy Media Press releases Contact information Job Seekers Job openings Open applications Follow us facebook twitter linkedin RSS Feed Terms of use

Sitemap Contact Worldwide Synthon company websites About Us Biopharmaceuticals Generics Products News Careers NEWS Synthon's latest news, press releases and publications. Home CORPORATE PRESS RELEASES 5/18/2016 Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients 9/28/2015 Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985 8/3/2015 Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Go to Press overview PUBLICATIONS Download Company brochure News News and Press Releases News in the Netherlands Contact Information Science Pipeline Biopharmaceuticals Pipeline Generics Scientific platforms Partners BD Biopharmaceuticals BD Generics Products Scientific platforms Strategy Media Press releases Contact information Job Seekers Job openings Open applications Follow us facebook twitter linkedin RSS Feed Terms of use